B-MS late-stage pipeline to launch three products a year
Published: 20-Dec-2001
Over the next 12 months, Bristol-Myers Squibb plans to submit an unprecedented number of regulatory submissions, including global regulatory filings for five new potential blockbuster compounds. The company has more than 50 compounds in its early and late-stage pipeline and more than 100 drug discovery programmes.
'Our Strategy for Growth plan, announced a year ago, has already delivered significant results,' said Peter R. Dolan, chairman and ceo. 'We believe we have the products that will allow us to launch three potential blockbuster products a year for several years starting in 2003. '
Within the next 12 months B-MS expects to submit global regulatory filings for the following potential best-in-class or first-in-class products:
Aripiprazole - a next-generation antipsychotic compound under investigation for the treatment of schizophrenia and related disorders. The company submitted the NDA for aripiprazole on 31 October and plans to submit for filing the Marketing Authorisation Application (MAA) in Europe by the end of the year. Erbitux (cetuximab) - a first-in-class monoclonal antibody that is being developed for initial use in treating advanced colorectal cancer. B-MS and ImClone Systems are also exploring its potential for treating other tumour types, including refractory head and neck tumors and pancreatic cancer. Vanlev (omapatrilat) is a novel NEP/ACE inhibitor that may offer a treatment alternative for high blood pressure. It is also being developed for congestive heart failure. Atazanavir - a protease inhibitor to be taken orally once-a-day. It has a favourable HIV resistance and lipid profile and has not been associated with elevated lipid levels. B-MS plans to complete the global regulatory submissions by the second half of 2002. Desquinolone - Des-6-fluoroquinolone is a novel antibiotic that has demonstrated excellent safety and resistance profiles. The company plans to complete global regulatory submissions for multiple indications in the second half of 2002. 'The next 12 months will be the most prolific period in Bristol-Myers Squibb discovery and development history,' said Dr Peter S. Ringrose, chief scientific office and president of Bristol-Myers Squibb Pharmaceutical Research Institute.
